Evolus, Inc. (NASDAQ:EOLS – Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a decrease of 6.6% from the March 15th total of 4,980,000 shares. Based on an average trading volume of 657,700 shares, the days-to-cover ratio is presently 7.1 days. Approximately 9.8% of the shares of the company are sold short.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on EOLS shares. Barclays upgraded shares of Evolus from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $10.00 to $16.00 in a research report on Monday, January 29th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Friday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, April 10th.
Insider Activity
Hedge Funds Weigh In On Evolus
Several institutional investors and hedge funds have recently made changes to their positions in EOLS. Point72 Hong Kong Ltd raised its holdings in Evolus by 979.7% in the first quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock valued at $26,000 after acquiring an additional 2,126 shares in the last quarter. Metropolitan Life Insurance Co NY acquired a new stake in shares of Evolus in the 1st quarter valued at about $26,000. Point72 Middle East FZE bought a new position in shares of Evolus during the fourth quarter worth about $39,000. Tower Research Capital LLC TRC grew its stake in Evolus by 453.6% in the third quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $51,000 after purchasing an additional 5,221 shares in the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in Evolus in the third quarter valued at about $54,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.
Evolus Trading Down 3.4 %
Shares of EOLS stock opened at $11.64 on Thursday. Evolus has a twelve month low of $7.07 and a twelve month high of $15.43. The company has a market capitalization of $674.42 million, a PE ratio of -10.68 and a beta of 1.45. The firm has a fifty day simple moving average of $13.67 and a 200-day simple moving average of $11.13.
Evolus (NASDAQ:EOLS – Get Free Report) last announced its earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The firm had revenue of $61.00 million during the quarter, compared to analyst estimates of $61.14 million. Equities research analysts predict that Evolus will post -0.51 EPS for the current year.
Evolus Company Profile
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Stories
- Five stocks we like better than Evolus
- Dividend Capture Strategy: What You Need to Know
- United Airlines Soars on Earnings Beat
- What is a Stock Market Index and How Do You Use Them?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Investing in large cap stocks: Diving into big caps
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.